Cyano-Substituted Cyclic Hydrazine for Selective JAK1/JAK2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK inhibitors lack selectivity, particularly for JAK1, leading to side effects such as immune-related issues and pulmonary embolism, necessitating the development of inhibitors with high selectivity for JAK1 and JAK2.
Innovation Solution
A cyano-substituted cyclic hydrazine derivative is developed, characterized by specific structural components and synthesis methods, offering high activity and selectivity for JAK1 and JAK2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing JAK inhibitors are used, then JAK family kinase activity is inhibited, but selectivity for JAK1 is poor leading to side effects
Solution Approach 1:
The patent applies local quality by introducing specific structural features (cyano group at position 4, cyclic hydrazine core) to create selective binding interactions with JAK1's unique structural characteristics. The compound's molecular structure is optimized to interact specifically with JAK1's catalytic pocket while avoiding JAK2 binding sites, achieving high selectivity through localized structural modifications.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituent positions, functional group types, steric configurations) to optimize binding affinity and selectivity. The cyano group at position 4 and the cyclic hydrazine structure are configured to create specific binding modes that favor JAK1 over JAK2, transforming the binding parameters to achieve high selectivity.
2Adaptability or versatility
If JAK inhibitors are used to treat autoimmune diseases, then disease symptoms are alleviated, but immune-related side effects occur
Solution Approach 1:
The patent applies segmentation by separating the binding interaction into specific components: the cyclic hydrazine core provides binding affinity while the cyano group at position 4 provides selectivity. This segmentation of functional groups allows the compound to target JAK1 specifically, maintaining therapeutic efficacy for autoimmune diseases while avoiding the non-selective inhibition that causes immune-related side effects.
3Adaptability or versatility
If non-selective JAK inhibitors are used, then broad JAK family inhibition is achieved, but pulmonary embolism risk increases
Solution Approach 1:
The patent applies the taking out principle by extracting the selective binding capability from the broader JAK inhibition profile. The compound is designed to selectively inhibit JAK1 while leaving JAK2 active, thereby maintaining the ability to treat conditions requiring JAK inhibition while removing the harmful non-selective inhibition that causes pulmonary embolism.
Data Source
AI summary
The present invention provides a cyano-substituted cyclic hydrazine derivative, comprising: a compound represented by the following structural formula or a stereoisomer, a geometric isomer, a tautomer, a racemate, a hydrate, a solvate, a metabolite and a pharmaceutically acceptable salt or a prodrug thereof The compound is used for prevention, treatment or alleviation of autoimmune diseases or proliferative diseases in patients, and/or for inhibiting or modulating protein kinase activity.